GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene Biotek Ltd (BOM:526139) » Definitions » Capex-to-Operating-Income

Transgene Biotek (BOM:526139) Capex-to-Operating-Income : 0.00 (As of Mar. 2025)


View and export this data going back to 2001. Start your Free Trial

What is Transgene Biotek Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Transgene Biotek's Capital Expenditure for the three months ended in Mar. 2025 was ₹0.00 Mil. Its Operating Income for the three months ended in Mar. 2025 was ₹-5.66 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Transgene Biotek Capex-to-Operating-Income Historical Data

The historical data trend for Transgene Biotek's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Biotek Capex-to-Operating-Income Chart

Transgene Biotek Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Transgene Biotek Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Transgene Biotek's Capex-to-Operating-Income

For the Biotechnology subindustry, Transgene Biotek's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Transgene Biotek's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's Capex-to-Operating-Income falls into.


;
;

Transgene Biotek Capex-to-Operating-Income Calculation

Transgene Biotek's Capex-to-Operating-Income for the fiscal year that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-16.995) / -12.165
=N/A

Transgene Biotek's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -5.656
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Transgene Biotek  (BOM:526139) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Transgene Biotek Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Transgene Biotek's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Transgene Biotek Business Description

Traded in Other Exchanges
N/A
Address
Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.

Transgene Biotek Headlines

No Headlines